Third Annual Meeting

πŸ“’ RITA-MI2 Partners met last Thursday 29th August in beautiful London for their annual meeting to take stock of the project 3 years after its launch. πŸŒπŸ‘©β€βš•οΈπŸ‘¨β€βš•οΈ A great opportunity for participants from all across Europe to discuss and plan the next 12 months...

20 recruitment centres already opened !

Regulatory approval has now been obtained for all participating coutries.βœ”οΈ Since the beginning of the RITA-MI2 trial in 2022, 20 recruitment centres, in France, the UK, Germany, Spain and the Czech Republic have opened for recruitment. πŸ‘ 4 additional centres, in...

Second Annual Meeting

πŸ“’The RITA-MI2 project Second Annual Meeting took place on Wednesday 21st June 2023, on-line. πŸ–₯πŸ“†πŸ“Š A great opportunity for the 25 participants from all across Europe to discuss about the project’s progress, 2 years after its launch. πŸ₯πŸ’—πŸ©ΊπŸ‘©β€βš•οΈπŸ‘©β€πŸ”¬πŸ§ͺπŸ”œ LinkedIn posts here and...

1st Annual Meeting

The RITA-MI2 project First Annual Meeting took place on Tuesday 21st June 2022, on-line. πŸ–₯πŸ“†πŸ“Š 23 project members working for one of the 13 project partners gathered one afternoon to present and discuss about the project’s first year and the next steps to be taken...

RITA-MI2 in clinical trials.gov

The RITA-MI2 trial is listed on clinicaltrials.gov, under registration number NCT05211401.   Study Description   Brief Summary The main objective is to compare the effect of a single injection of two doses of rituximab versus placebo on 6 months left...